Real world points to SGLT-2 blockers advantage

Nat Biotechnol. 2017 Apr 11;35(4):297. doi: 10.1038/nbt0417-297c.
No abstract available

MeSH terms

  • Benzhydryl Compounds / therapeutic use*
  • Canagliflozin / therapeutic use
  • Cardiovascular Abnormalities / blood
  • Cardiovascular Abnormalities / etiology
  • Cardiovascular Abnormalities / prevention & control*
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / prevention & control*
  • Glucose / metabolism
  • Glucosides / therapeutic use*
  • Humans
  • Kidney Tubules, Proximal / drug effects
  • Sodium-Glucose Transporter 2 / therapeutic use
  • Sodium-Glucose Transporter 2 Inhibitors*

Substances

  • Benzhydryl Compounds
  • Glucosides
  • SLC5A2 protein, human
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors
  • Canagliflozin
  • dapagliflozin
  • Glucose